Showing results (1351-1360 of 1,385) with videos related to

Sort By:
Pageof 139
The Lancet. Gastroenterology & Hepatology|March 3, 2019
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort studyNicholas A Kennedy, Graham A Heap, Harry D Green, et al.
Nature|November 17, 2022
Enterococci enhance Clostridioides difficile pathogenesisAlexander B Smith, Matthew L Jenior, Orlaith Keenan, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Stroke|December 22, 2023
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial ModelingStephanie Hage, Serena Kinkade, Romuald Girard, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial ModelingStephanie Hage, Serena Kinkade, Romuald Girard, et al.
Journal of Crohn'S & Colitis|January 26, 2026
Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trialMohammed Nabil Quraishi, Catherine A Moakes, Mehmet Yalchin, et al.
Gut|March 23, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximabNicholas A Kennedy, James R Goodhand, Claire Bewshea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ M Weiss, T Csoszi, M Maglakelidze, et al.
Pageof 139